We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
AusPAR: Vyalev
Australian Public Assessment Report
Device/Product Name
Vyalev
Active ingredients
Foslevodopa and Foscarbidopa
AusPAR Date
Published
Sponsor
Submission Number
PM-2021-03724-1-1
Submission Type
New fixed dose combination medicine Vyalev, containing 2 new chemical entities (foslevodopa and foscarbidopa)
Decision
Approved